LeonaBio, Inc. (LONA)
| Market Cap | 98.82M +743.7% |
| Revenue (ttm) | n/a |
| Net Income | -129.41M |
| EPS | -16.06 |
| Shares Out | 9.39M |
| PE Ratio | n/a |
| Forward PE | n/a |
| Dividend | n/a |
| Ex-Dividend Date | n/a |
| Volume | 60,850 |
| Open | 10.37 |
| Previous Close | 10.32 |
| Day's Range | 9.68 - 10.59 |
| 52-Week Range | 2.51 - 14.21 |
| Beta | 1.98 |
| Analysts | Buy |
| Price Target | 10.00 (-4.94%) |
| Earnings Date | May 7, 2026 |
About LONA
LeonaBio, Inc., clinical-stage biopharmaceutical company, engages in the development of novel therapeutics for high unmet medical needs, including treatment-resistant metastatic breast cancer and amyotrophic lateral sclerosis. The company’s lead products include lasofoxifene and ATH-1105, a novel small molecule therapies with the potential to address devastating diseases where current treatment options are limited or ineffective. Its product pipeline includes ATH-1105 for the treatment of amyotrophic lateral sclerosis, which is in phase 1 clini... [Read more]
Financial Performance
Financial StatementsAnalyst Summary
According to one analyst, the rating for LONA stock is "Buy" and the 12-month stock price target is $10.0.
News
LeonaBio Reports First Quarter 2026 Financial Results and Provides Business Update
Advancing Phase 3 Lasofoxifene Development Program of Novel Selective Estrogen Receptor Modulator, a Potential Multi-Billion Dollar Opportunity as Treatment Option for Patients with ESR1-Mutations Exp...
LeonaBio Enhances Board of Directors with Appointments of Fred Callori, J.D., Natalie Holles and Peter B.
BOTHELL, Wash., May 07, 2026 (GLOBE NEWSWIRE) -- LeonaBio, Inc. (NASDAQ: LONA), a clinical-stage biopharmaceutical company dedicated to the development of novel therapeutics for diseases with high unm...
LeonaBio Transcript: Status update
Lasofoxifene is advancing as a promising, well-tolerated oral therapy for ER-positive, ESR1-mutated metastatic breast cancer, showing strong efficacy in combination with abemaciclib and addressing key resistance mechanisms. The pivotal ELAINE 3 trial is over halfway enrolled, with top-line data expected in 2027.
LeonaBio to Host Virtual Key Opinion Leader Event Highlighting Potential of Lasofoxifene in Treatment-Resistant ER+/HER2-, ESR1-Mutated Metastatic Breast Cancer
Management to be Joined by Two Clinical Leaders in the Breast Cancer Field Expected to Complete Enrollment in Ongoing ELAINE-3 Phase 3 Registrational Study of Lasofoxifene in Metastatic Breast Cancer...
LeonaBio presented data on lasofoxifene research at AACR26
LeonaBio (LONA) attended the American Association for Cancer Research Annual Meeting 2026, AACR26, where independent researchers at Virginia Commonwealth University’s Massey Comprehensive Cancer Cente...
Eight option delistings on April 20th
Option delistings effective April 20th include Leonabio, Inc. (LONA), Light & Wonder Inc (LNWO), Heritage Commerce (HTBK), Captivision Inc (CPTAF), Clearside Biomedical, Inc (CLSDQ), Biodesix (BDSX), ...
LeonaBio price target raised to $16 from $10 at Mizuho
Mizuho raised the firm’s price target on LeonaBio (LONA) to $16 from $10 and keeps an Outperform rating on the shares post the Q4 report. The firm views LeonaBio as…
LeonaBio Reports Full Year 2025 Financial Results and Provides Business Update
Acquired License to Phase 3 Lasofoxifene Development Program of Novel Selective Estrogen Receptor Modulator (SERM), a Potential Multi-Billion Dollar Opportunity as Treatment Option for Breast Cancer P...
LeonaBio Transcript: EGM 2026
Six proposals, including share issuances, an equity plan, and an increase in authorized shares, were presented and all approved by the required majority. No questions were raised by stockholders, and final results will be filed with the SEC.
LeonaBio initiated with an Overweight at Cantor Fitzgerald
Cantor Fitzgerald initiated coverage of LeonaBio (LONA) with an Overweight rating and no price target The company’s lasofoxifene has been re-purposed for the treatment of ER+ metastatic breast cancer ...
LeonaBio upgraded to Outperform from Neutral at Mizuho
Mizuho upgraded LeonaBio (LONA) to Outperform from Neutral with a $10 price target which implies 120% upside potential. The firm upgraded the shares after introducing projections for LeonaBio’s new le...
LeonaBio appoints Kubik as Chief Business Officer
LeonaBio (LONA) announced the appointment of Mark Kubik as Chief Business Officer. Kubik previously served as a strategic consultant to LeonaBio.
LeonaBio Appoints Industry Veteran Mark F. Kubik as Chief Business Officer
Brings more than 25 years of biopharma business development and corporate strategy expertise Brings more than 25 years of biopharma business development and corporate strategy expertise
LeonaBio files to sell 5.5M shares of common stock for holders
16:45 EST LeonaBio (LONA) files to sell 5.5M shares of common stock for holders
Athira Pharma recovers from Alzheimer's failure with breast cancer pivot and $90M investment
In a remarkable pivot, Athira Pharma has a deal to test a promising breast cancer drug and landed $90 million in upfront funding from investors.
LeonaBio Transcript: Status Update
Announced acquisition of lasofoxifene rights, expanding the pipeline with a phase III breast cancer asset and advancing ALS candidate ATH-1105. Raised $90 million to fund key milestones, with both programs targeting pivotal data in 2027. Lasofoxifene offers strong clinical and commercial potential.
Athira Pharma Announces Exclusive License to Lasofoxifene Phase 3 Development Program for Metastatic Breast Cancer Candidate and a Financing for up to $236 Million
Phase 3 Development Program of Novel Selective Estrogen Receptor Modulator (SERM) Represents Potential Multi-Billion Dollar Opportunity as Treatment Option for Patients with ESR1-Mutations
Athira Pharma Announces Reverse Stock Split
BOTHELL, Wash., Sept. 11, 2025 (GLOBE NEWSWIRE) -- Athira Pharma, Inc. (“Athira” or “Company”) (NASDAQ: ATHA), a clinical stage biopharmaceutical company focused on developing small molecules to resto...
Athira Pharma to Present Data from First-in-Human Phase 1 Clinical Trial of ATH-1105 at the 4th Annual ALS Drug Development Summit
Data from Phase 1 clinical trial of ATH-1105 in healthy volunteers showed a favorable safety and tolerability profile; dose proportional pharmacokinetics and CNS penetration support continued clinical...
Athira Pharma Reports First Quarter 2025 Financial Results and Pipeline and Business Updates
Completed healthy volunteer Phase 1 clinical study of ATH-1105 as a potential treatment for amyotrophic lateral sclerosis (ALS); full healthy volunteer data expected in 2H25
Athira Pharma Reports Full Year 2024 Financial Results and Pipeline and Business Updates
Completed healthy volunteer Phase 1 clinical study of ATH-1105 as a potential treatment for amyotrophic lateral sclerosis (ALS)
Seattle biotech firm Athira Pharma will pay $4M to settle allegations related to research misconduct
Seattle-area biotech company Athira Pharma agreed to pay $4.
Athira Pharma Presents Preclinical Data Highlighting Neuroprotective Effects of ATH-1105 in Models of ALS at Motor Neurone Disease Association's 35th International Symposium on ALS/MND
BOTHELL, Wash., Dec. 06, 2024 (GLOBE NEWSWIRE) -- Athira Pharma, Inc. (NASDAQ: ATHA), a clinical-stage biopharmaceutical company focused on developing small molecules to restore neuronal health and sl...
Athira Pharma Reports Third Quarter 2024 Financial Results and Pipeline and Business Updates
Expects to complete healthy volunteer Phase 1 clinical study of ATH-1105 by year end and begin dosing ALS patients in 2025 Expects to complete healthy volunteer Phase 1 clinical study of ATH-1105 by y...
Athira Pharma laying off 49 employees, about 70% of workforce, as part of restructuring
Seattle-based biotech company Athira Pharma is laying off 49 people, or about 70% of its workforce, as part of cost-cutting measures and a restructuring.